Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Forensic applicability of autosomal insertion/deletion loci in Chinese Daur ethnic group and genetic affinity evaluations between Daur group and reference populations.

Legal medicine (Tokyo, Japan)·2020
Same author

Dental caries experience and related risk indicators of 12-year-old students in Jilin, China.

Medicine·2020
Same author

The role of NAC transcription factor in plant cold response.

Plant signaling & behavior·2020
Same author

Monocyte-Derived Leukemia-Associated Macrophages Facilitate Extramedullary Distribution of T-cell Acute Lymphoblastic Leukemia Cells.

Cancer research·2020
Same author

An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway.

Cancer gene therapy·2020
Same author

A population-based survey for dietary patterns and prediabetes among 7555 Chinese adults in urban and rural areas in Jiangsu Province.

Scientific reports·2020

Related Experiment Video

Updated: Jun 11, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K

Targeting GPRC5D for multiple myeloma therapy.

Dian Zhou1,2, Ying Wang1,2, Chong Chen1,2

  • 1Department of Hematology, Affiliated Hospital of Xuzhou Medical University, #99 West Huaihai Road, Xuzhou, 221002, Jiangsu, China.

Journal of Hematology & Oncology
|September 28, 2024
PubMed
Summary
This summary is machine-generated.

G protein-coupled receptor class C group 5 member D (GPRC5D) is a promising immunotherapy target for multiple myeloma (MM). Research is exploring GPRC5D-targeting therapies like bispecific antibodies and CAR T-cells for relapsed/refractory MM.

Keywords:
Bispecific antibodiesChimeric antigen receptor T cellG protein-coupled receptor class C group 5 member DImmunotherapyMultiple myeloma

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K

Related Experiment Videos

Last Updated: Jun 11, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • G protein-coupled receptor class C group 5 member D (GPRC5D) shows near-universal expression on plasma cells.
  • GPRC5D has limited expression on essential normal tissues, making it an attractive immunotherapy target.
  • Multiple myeloma (MM) remains a significant challenge, particularly in relapsed/refractory settings.

Purpose of the Study:

  • To review the biological characteristics of GPRC5D.
  • To summarize the translational progress of GPRC5D-targeting immunotherapies.
  • To highlight the potential of GPRC5D as a therapeutic target in multiple myeloma.

Main Methods:

  • Review of current scientific literature on GPRC5D.
  • Analysis of preclinical and clinical data for GPRC5D-targeting agents.
  • Synthesis of information on therapeutic strategies including bispecific antibodies (BsAbs), chimeric antigen receptor (CAR) T cells, and antibody-drug conjugates (ADCs).

Main Results:

  • GPRC5D-targeting immunotherapies, including BsAbs, CAR T cells, and ADCs, show promise in relapsed/refractory MM (R/R MM).
  • The unique expression profile of GPRC5D supports its potential as a highly specific target.
  • Ongoing research focuses on optimizing these therapies and exploring combination strategies.

Conclusions:

  • GPRC5D represents a viable and promising target for novel immunotherapies in multiple myeloma.
  • Further clinical trials are essential to establish long-term efficacy and optimal treatment paradigms.
  • Combination therapies targeting GPRC5D alongside other antigens or existing treatments may overcome MM resistance.